Acute toxicity profile of 1-butyl-3-methylimidazolium chloride.
Landry
T D
TD
Toxicology Research and Consulting, The Dow Chemical Company, 1803 B, Midland, MI 48674, USA.
Brooks
K
K
Poche
D
D
Woolhiser
M
M
D000279:Administration, Cutaneous; D000284:Administration, Oral; D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects; D003231:Conjunctivitis / Q000139:chemically induced; D003877:Dermatitis, Contact / Q000209:etiology; D004126:Dimethylformamide / Q000633:toxicity; D004357:Drug Synergism; D005123:Eye / Q000187:drug effects* / Q000473:pathology; D005260:Female; D007093:Imidazoles / Q000633:toxicity*; D007928:Lethal Dose 50; D008198:Lymph Nodes / Q000187:drug effects* / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D011817:Rabbits; D051381:Rats; D011916:Rats, Inbred F344; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D023422:Skin Irritancy Tests
D007093:Imidazoles; C502841:1-butyl-3-methylimidazolium chloride; D004126:Dimethylformamide